IRIS
Puccini, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.478
AS - Asia 1.907
EU - Europa 467
SA - Sud America 453
Continente sconosciuto - Info sul continente non disponibili 106
AF - Africa 50
OC - Oceania 1
Totale 5.462
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.371
SG - Singapore 1.002
CN - Cina 407
BR - Brasile 350
IT - Italia 223
VN - Vietnam 194
HK - Hong Kong 86
CA - Canada 52
FR - Francia 45
IN - India 45
DE - Germania 37
GB - Regno Unito 35
AR - Argentina 31
BD - Bangladesh 31
MX - Messico 24
EC - Ecuador 20
ID - Indonesia 20
AT - Austria 19
TR - Turchia 17
CO - Colombia 15
CL - Cile 14
ES - Italia 13
MY - Malesia 13
PL - Polonia 13
JP - Giappone 12
MA - Marocco 12
NL - Olanda 11
FI - Finlandia 10
IQ - Iraq 10
JM - Giamaica 10
SE - Svezia 10
ZA - Sudafrica 10
PH - Filippine 9
RU - Federazione Russa 9
SA - Arabia Saudita 9
VE - Venezuela 9
EG - Egitto 8
HN - Honduras 7
UY - Uruguay 7
UA - Ucraina 6
AE - Emirati Arabi Uniti 5
EE - Estonia 5
KZ - Kazakistan 5
LT - Lituania 5
PY - Paraguay 5
DZ - Algeria 4
KE - Kenya 4
NP - Nepal 4
PK - Pakistan 4
TN - Tunisia 4
CR - Costa Rica 3
CY - Cipro 3
QA - Qatar 3
RS - Serbia 3
UZ - Uzbekistan 3
BB - Barbados 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LU - Lussemburgo 2
LV - Lettonia 2
OM - Oman 2
PS - Palestinian Territory 2
RO - Romania 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
ZM - Zambia 2
AD - Andorra 1
AL - Albania 1
AO - Angola 1
AU - Australia 1
AZ - Azerbaigian 1
BE - Belgio 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BS - Bahamas 1
CG - Congo 1
CH - Svizzera 1
DK - Danimarca 1
ET - Etiopia 1
GA - Gabon 1
GT - Guatemala 1
IE - Irlanda 1
IL - Israele 1
IM - Isola di Man 1
IR - Iran 1
KG - Kirghizistan 1
KR - Corea 1
KW - Kuwait 1
LK - Sri Lanka 1
LY - Libia 1
MK - Macedonia 1
MN - Mongolia 1
NG - Nigeria 1
Totale 5.348
Salva come PNG Salva come JPEG
Città #
Dallas 516
Singapore 407
San Jose 247
Ashburn 233
Beijing 174
The Dalles 150
Council Bluffs 100
Santa Clara 87
Hong Kong 86
Ho Chi Minh City 83
Los Angeles 70
Milan 69
New York 51
Buffalo 37
Hanoi 33
São Paulo 30
Rome 29
Shanghai 23
Chicago 19
Assago 16
Naples 16
Mexico City 15
Phoenix 15
Chennai 14
Montreal 14
Curitiba 13
Orem 13
Toronto 13
Philadelphia 12
Princeton 11
Atlanta 10
Belo Horizonte 10
Guayaquil 10
Helsinki 10
Las Vegas 10
Rio de Janeiro 10
Houston 9
London 9
Warsaw 9
Boston 8
Brasília 8
Brooklyn 8
Charlotte 8
Denver 8
Dhaka 8
Haiphong 8
Hải Dương 8
Jakarta 8
Nuremberg 8
Queens 8
Seattle 8
Tongling 8
Vienna 8
Ankara 7
Biên Hòa 7
Pasadena 7
Porto Alegre 7
Quito 7
Tokyo 7
Turin 7
Abbeville 6
Kuala Lumpur 6
Montevideo 6
Stockholm 6
Baghdad 5
Bogotá 5
Bologna 5
Can Tho 5
Chengdu 5
Frankfurt am Main 5
Genoa 5
Goiânia 5
Hillsboro 5
Johannesburg 5
Kansas City 5
Louisville 5
Manaus 5
Miami 5
Paris 5
Pittsburgh 5
Reston 5
Ribeirão Preto 5
Alexandria 4
Calgary 4
Camden 4
Campinas 4
Charleston 4
Da Nang 4
Delhi 4
Ha Long 4
Istanbul 4
Jersey City 4
Kingston 4
Lấp Vò 4
Mumbai 4
San Francisco 4
Santiago 4
São José dos Campos 4
Astana 3
Birmingham 3
Totale 3.028
Salva come PNG Salva come JPEG
Nome #
Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life 441
A new prognostic and predictive tool for shared decision making in stage III colon cancer 112
Barriers and Facilitators in Diagnostic Pathways That Align Universal Tumor Screening and Mainstream Genetic Testing for Lynch Syndrome in Colorectal Cancer: Protocol for a Scoping Review With a Narrative Synthesis 110
Streamlining the diagnostic pathway for Lynch syndrome in colorectal cancer patients: a 10-year experience in a single Italian Cancer Center 100
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials 100
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy 99
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 94
Impact of RAS/BRAF V600E mutations on the tumor immune microenvironment in mismatch repair deficient /microsatellite instability colorectal cancers 94
Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets 90
Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer 90
BRAFV600E immunohistochemistry can reliably substitute BRAF molecular testing in the Lynch syndrome screening algorithm in colorectal cancer 80
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort 79
Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients 77
Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study 75
Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer 72
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3 72
Prognostic impact of depth of response and early tumour shrinkage in patients with BRAFV600E-mutated metastatic colorectal cancer treated with targeted therapy 72
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial 71
Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma 69
Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors 68
Fertility Preservation Practices and Gastrointestinal (GI) Oncologist in Europe: A Pan-European study 67
The impact of ARID1A mutation on molecular characteristics in colorectal cancer 66
Lynch Syndrome: From Multidisciplinary Management to Precision Prevention 66
Prevalence and type of MMR expression heterogeneity in colorectal adenocarcinoma: therapeutic implications and reporting 65
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 65
Microsatellite-Instability-High Advanced Colorectal Cancer 65
Colorectal cancer: epigenetic alterations and their clinical implications 62
A polymorphism within the Vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/ bevacizumab or FOLFIRI/Cetuximab 58
Research training, barriers, and career development needs of early-career investigators in oncology: an EORTC survey-based study 58
Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients 57
First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy? 56
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset 56
New perspectives for colorectal cancer 56
Impact of Sociodemographic Disparities and Insurance Status on Survival of Patients with Early-Onset Colorectal Cancer 55
Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis 55
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective 54
Molecular profile of BRCA-mutated biliary tract cancers 54
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer 54
Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study 54
Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) 53
Prognostic impact of pathological complete response and response-adapted outcomes in patients with gastroesophageal adenocarcinoma treated with neoadjuvant or perioperative treatments: a multicentric cohort study 52
WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype 52
Treatment of patients with BRAF-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset 52
What We Know About Stage II and III Colon Cancer: It's Still Not Enough 51
Management of Advanced Small Bowel Cancer 51
Young Patients with Colorectal Cancer: Risk, Screening, and Treatment 51
B cell and B cell-related pathways for novel cancer treatments 50
Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM) 50
Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study 50
Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer 50
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy 49
Redefining Colorectal Cancer by Tumor Biology 49
Tackling hurdles in front of young clinical investigators in oncology – Results from an international survey 49
Cisplatin-related Atrial Fibrillation during PEB Chemotherapy for Testicular Seminoma: A Case Report 48
Editorial: New therapeutic approaches in microsatellite stable colorectal cancer patients 48
Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers 47
Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets 47
Total Neoadjuvant Treatment for Locally Advanced Rectal Cancer Patients: Where Do We Stand? 47
Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma 46
Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions 46
ctDNA to Guide Treatment of Colorectal Cancer: Ready for Standard of Care? 46
The role of tumor angiogenesis as a therapeutic target in colorectal cancer 45
From walls to wonder: Talking about spaces tailored for adolescents and young adults with cancer 45
Outlooks on Epstein-Barr virus associated gastric cancer 45
Safety and Tolerability of c-MET Inhibitors in Cancer 44
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 44
Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients 44
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies 44
The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer 42
Metastatic sarcoma: tailored strategies for a heterogeneous disease 42
Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer 41
Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence? 41
Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives 40
Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers 40
The urgent need to improve the tools to assess clinical benefit and value of cancer treatment 39
The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives 39
Universal tumor screening and mainstream genetic testing for Lynch syndrome in colorectal cancer: a scoping review of barriers and facilitators 38
Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients 38
Evaluating mismatch repair deficiency in colorectal cancer biopsy specimens 36
Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors 36
Maintenance Olaparib for Metastatic Pancreatic Cancer 36
Molecular Variances Between Right- and Left-sided Colon Cancers 35
Routinely Updating Patients With Cancer About Variant of Uncertain Significance Reclassifications: A Premature Responsibility for Community Oncologists 35
Reliability of patient-reported toxicities during adjuvant chemotherapy 33
Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3 33
Practice-changing updates in the adjuvant and metastatic setting 32
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system 30
The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials 30
Circulating tumour DNA in oligometastatic oesophago-gastric cancers: applications, challenges, and future directions 21
Knowledge and resources gaps for adolescent and young adult (AYA) cancer patients: Results from survAYA, an Italian National Survey 19
Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy 18
Absence of co-occurrence between HER2 amplification and dMMR/MSI in a large multicentric colorectal cancer cohort 17
The role of circulating tumor DNA (ctDNA) to detect minimal residual disease in locally advanced gastroesophageal carcinoma: the BUTTERFLY study 14
Heterogeneity of pathological tumour response in patients with multiple colorectal liver metastases undergoing resection after preoperative chemotherapy 14
Artificial intelligence-based prediction of claudin 18.2 expression and immune phenotype from routine histology to guide treatment decisions in patients with gastric cancer 13
Announcing The Lancet Regional Health—Europe series on the alarming surge of early-onset colorectal cancer: a multidisciplinary call to action 13
Long non-coding RNAs in colorectal cancer: shaping the tumour microenvironment and advancing precision oncology 12
Irinotecan plus cetuximab rechallenge versus trifluridine/tipiracil plus bevacizumab as third-line treatment in circulating tumor DNA–selected metastatic colorectal cancer (ROMANCE trial) 2
Totale 5.462
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.360
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.360
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202412 0 0 0 0 0 0 0 0 0 4 4 4
2024/2025787 1 2 1 4 1 122 78 109 74 180 75 140
2025/20263.621 356 227 546 385 91 155 580 208 280 232 202 359
2026/20271.042 192 238 585 27 0 0 0 0 0 0 0 0
Totale 5.462